Skip to main
  1. Stocks
  2. Nuvation Bio
  3. Forecast
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is viewed favorably because Ibtrozi already has a meaningful commercial head start in ROS1+ NSCLC, with durable efficacy and a differentiated safety profile that may support physician adoption despite lighter-than-expected 3Q26 revenue of $27.5M and competitive pressure. The investment case is further strengthened by safusidenib, which is seen as the main value creator thanks to recent BTD momentum, a 79.1% 36-month PFS rate in Japanese patients, and development milestones still on track for 2027 data, including the expanded SIGMA study. With the company described as well capitalized and its valuation anchored by two assets, Ibtrozi and safusidenib, the combination of near-term launch optionality and long-duration pipeline upside supports a constructive fundamental outlook.

Bears say

Nuvation Bio is facing a weaker-than-expected launch profile for Ibtrozi, with revenue of $27.5M falling below both the $30.5M estimate and the Street’s $29.2M as the overall ROS1 TKI market declined 15% and new patient starts stayed flat at about 160, including fewer critical 1L adds. The business also faces commercialization friction from a small, competitive indication, potential dose-dependent pricing pressure, and safety concerns such as edema, dyspnea, and weight gain that could limit adoption and prolong patient stacking. Beyond the launch, the company’s outlook is further burdened by early-stage pipeline execution risk, dependence on Japan-linked revenue streams, potential dilution from additional financing, and repayment obligations tied to the Sagard Health Partners deal.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Nuvation Bio (NUVB) Analyst Forecast & Price Prediction

Get the latest Nuvation Bio (NUVB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nuvation Bio (NUVB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Nuvation Bio (NUVB) Analyst Forecast & Price Prediction

Get the latest Nuvation Bio (NUVB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nuvation Bio (NUVB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NUVB stock data and trends